Beam Therapeutics Net Worth
Beam Therapeutics Net Worth Breakdown | BEAM |
Beam Therapeutics Net Worth Analysis
Beam Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Beam Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Beam Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Beam Therapeutics' net worth analysis. One common approach is to calculate Beam Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Beam Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Beam Therapeutics' net worth. This approach calculates the present value of Beam Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Beam Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Beam Therapeutics' net worth. This involves comparing Beam Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Beam Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Beam Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Beam Therapeutics' net worth research are outlined below:
| Beam Therapeutics generated a negative expected return over the last 90 days | |
| Beam Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 63.52 M. Net Loss for the year was (376.74 M) with loss before overhead, payroll, taxes, and interest of (304.04 M). | |
| Beam Therapeutics currently holds about 1.09 B in cash with (347.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.9. | |
| Over 79.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: CRISPR Therapeutics Stock Trades Near 52-Week Low Time to Buy or Sell |
Beam Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Beam Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Beam Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Beam Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Beam Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Beam Therapeutics backward and forwards among themselves. Beam Therapeutics' institutional investor refers to the entity that pools money to purchase Beam Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-12-31 | 1.8 M | Temasek Holdings Ltd. | 2024-12-31 | 1.8 M | Geode Capital Management, Llc | 2024-12-31 | 1.8 M | Kynam Capital Management, Lp | 2024-12-31 | 1.8 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 1.8 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.5 M | Redmile Group, Llc | 2024-12-31 | 1.5 M | Bellevue Group Ag | 2024-12-31 | 1.5 M | Casdin Capital, Llc | 2024-12-31 | 1.2 M | Farallon Capital Management, L.l.c. | 2024-12-31 | 8.2 M | Blackrock Inc | 2024-12-31 | 7.7 M |
Follow Beam Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.36 B.Market Cap |
|
Project Beam Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.45) | (0.43) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (0.51) | (0.54) |
When accessing Beam Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Beam Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Beam Therapeutics' profitability and make more informed investment decisions.
Evaluate Beam Therapeutics' management efficiency
Beam Therapeutics has return on total asset (ROA) of (0.2026) % which means that it has lost $0.2026 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4394) %, meaning that it created substantial loss on money invested by shareholders. Beam Therapeutics' management efficiency ratios could be used to measure how well Beam Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 20th of March 2025, Return On Tangible Assets is likely to drop to -0.36. In addition to that, Return On Capital Employed is likely to grow to -0.43. At this time, Beam Therapeutics' Other Current Assets are very stable compared to the past year. As of the 20th of March 2025, Net Tangible Assets is likely to grow to about 885.7 M, while Non Current Assets Total are likely to drop about 200.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 8.91 | 5.57 | |
| Tangible Book Value Per Share | 8.91 | 5.57 | |
| Enterprise Value Over EBITDA | (4.62) | (4.85) | |
| Price Book Value Ratio | 2.78 | 2.92 | |
| Enterprise Value Multiple | (4.62) | (4.85) | |
| Price Fair Value | 2.78 | 2.92 | |
| Enterprise Value | 1.9 B | 3.2 B |
Evaluating the management effectiveness of Beam Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Beam Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 24.6555 | Revenue | Quarterly Revenue Growth (0.91) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Beam Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Beam Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Beam Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Beam Therapeutics Corporate Filings
8K | 10th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 20th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F3 | 19th of December 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Beam Therapeutics Earnings per Share Projection vs Actual
Beam Therapeutics Corporate Management
| Manmohan Singh | Chief Officer | Profile | |
| Nicole Gaudelli | CoFounder | Profile | |
| Brian Riley | VP Operations | Profile | |
| Susan OConnor | Chief Officer | Profile | |
| Alexis Komor | CoFounder | Profile | |
| Amy MD | Chief Officer | Profile | |
| Suzanne Fleming | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.58) | Revenue Per Share | Quarterly Revenue Growth (0.91) | Return On Assets | Return On Equity |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.